March/April 2010, Vol 3, No 2

Business

Obesity: Effective Treatment Requires Change in Payers' Perspective
Rhonda Greenapple, MSPH
; Jackie Ngai, MS
Stakeholder Perspective by Jeff Januska, PharmD
Health Insurance Premium Increases for the 5 Largest School Districts in the United States, 2004-2008
John R. Cantillo, MBA
Stakeholder Perspective by F. Randy Vogenberg, RPh, PhD

Clinical

Evolving Trends in Insulin Delivery: In Pursuit of Improvements in Diabetes Management
Firas Akhrass, MD
; Nancy Skinner, RN
; Kimberly Boswell, MD
; Luther B. Travis, MD
Stakeholder Perspective by James V. Felicetta, MD
Healthcare Costs Associated with Switching from Brand to Generic Levothyroxine
Michael Katz, PharmD
; Joseph Scherger, MD, MPH
; Scott Conard, MD
; Leslie Montejano, CCRP
; Stella Chang, MPH
Stakeholder Perspective by Michael S. Jacobs, RPh

Regulatory

Pay-for-Performance Initiatives: Modest Benefits for Improving Healthcare Quality
Amit Sura, MD, MBA
; Nirav R. Shah, MD, MPH
Stakeholder Perspective by Steven T. Kmucha, MD, JD

Industry Trends

Pharmacogenomics and Drug Development
Michael F. Murphy, MD, PhD

Generic Drug Trends

First Anti-Inflammatory Generic Drug Promising New Therapy for Diabetes
Dalia Buffery, MA, ABD

Drug Pipeline

The Cardiovascular Pipeline: ACC 2010 Features Late-Stage Drugs
Wayne Kuznar

Meeting Highlights

NCCN Panel Debates the Economics of Cancer Care
Caroline Helwick
PET Scans Not Recommended for Most Patients with Breast Cancer: Potential New Controversy in Breast Cancer Testing
Caroline Helwick